Letters by company
Axsome Therapeutics, Inc.
2 letters discussing AXSM. Everything written about it on this site is on its ticker page.
- Baird Equity Asset Management Q2 2026 Commentary and Market Outlook Baird Small/Mid Cap Growth added software, AI-infrastructure industrials and commercial-stage therapeutics while exiting holdings where conviction or the original thesis had weakened. The strategy argues that data-center spending supports demand for cooling, power and infrastructure, but maintains discipline as AI-led market leadership becomes increasingly concentrated. Q2 2026 AAON $6.4BAGYS $3.5BALKS $7.8B
- GROW Funds Q4 2025 Investor Letter GROW Funds shifted portfolios toward healthcare, citing novel therapies and less cyclical demand, while continuing to trim holdings at price targets and sell positions where the thesis changed. The firm retained Mama’s Creations and Axsome Therapeutics, and argues that MDxHealth’s selloff overlooked its diagnostics growth and relative valuation. Q4 2025 AMZN $2.8TAXSM $7.5BDEPW